(Q37826118)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

The role of Beta-blockers as first-line therapy in hypertension (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

main subject

arterial hypertension

0 references

author

Antonio M. Leone

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Alberto Ranieri De Caterina

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

Current Atherosclerosis Reports

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

147-153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11883-010-0157-9

19 January 2020

exact match

0 references

cites work

Hypertension treatment and control in five European countries, Canada, and the United States

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Patient and provider perceptions of hypertension treatment: do they agree?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Presence of a Serum Vasoconstrictive Factor Following Unilateral Nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Expert consensus document on beta-adrenergic receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Why beta-blockers should not be used as first choice in uncomplicated hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Atenolol in hypertension: is it a wise choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Resting heart rate in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Use of beta-blockers in obesity hypertension: potential role of weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

beta-Blockers in hypertension: is carvedilol different?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Body weight changes with beta-blocker use: results from GEMINI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0157-9

21 January 2018

1 reference

12 December 2020

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

1 reference

12 December 2020

Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes

1 reference

12 December 2020

Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions.

1 reference

12 December 2020

Beta-blockers for hypertension

1 reference

12 December 2020

Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism

1 reference

12 December 2020

Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow-up study of atenolol

1 reference

12 December 2020

Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).

1 reference

12 December 2020

The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics

1 reference

12 December 2020

Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments

1 reference

12 December 2020

10.1007/S11883-010-0157-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21207202%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference